<!DOCTYPE html>
<html lang="en-us">
  <head>
    <meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta name="generator" content="Hugo 0.18.1" />


<title>CD19-Targeted CAR T Cells in Haematologic malignancies - A Hugo website</title>
<meta property="og:title" content="CD19-Targeted CAR T Cells in Haematologic malignancies - A Hugo website">



  







<link rel="stylesheet" href="../../../../css/fonts.css" media="all">
<link rel="stylesheet" href="../../../../css/main.css" media="all">



  </head>
  <body>
    <div class="wrapper">
      <header class="header">
        <nav class="nav">
  <a href="../../../../" class="nav-logo">
    <img src="../../../../images/logo.png"
         width="50"
         height="50"
         alt="Logo">
  </a>

  <ul class="nav-links">
    
    <li><a href="../../../../about/">About</a></li>
    
    <li><a href="https://github.com/rstudio/blogdown">GitHub</a></li>
    
    <li><a href="https://twitter.com/rstudio">Twitter</a></li>
    
  </ul>
</nav>

      </header>


<main class="content" role="main">

  <article class="article">
    
    <span class="article-duration">3 min read</span>
    

    <h1 class="article-title">CD19-Targeted CAR T Cells in Haematologic malignancies</h1>

    
    <span class="article-date">0001/01/01</span>
    

    <div class="article-content">
      

<p>Speaker: Jae Park, MD / Memorial Sloan Kettering Cancer Center | Specialized in ALL CLL NHL</p>

<h2 id="cd19-targeted-car-t-cells">CD19-Targeted CAR T cells</h2>

<h3 id="contents">Contents</h3>

<p><img src="http://media4.asco.org/156/9447/110503/110503_video_pvhr.jpg" alt="Gen of 19-28z CAR" /></p>

<ul>
<li>Ab + T cell receptor -&gt; chimeric</li>
<li>MHC presentation해서 보는게 아니라 Ab처럼 binding하지만 Action은 T cell</li>
<li>두개를 합친것. 어떻게 clinic에 사용할 것인가?</li>
<li>Stable expression할 수 있다.</li>
</ul>

<p><img src="https://www.mskcc.org/sites/default/files/styles/large/public/node/39453/image/msk402-cartcell-infographic327.jpg" alt="Process" />
<a href="https://www.mskcc.org/blog/car-t-cell-therapy-growing-area-research">https://www.mskcc.org/blog/car-t-cell-therapy-growing-area-research</a></p>

<ul>
<li>Average 60%정도 replication하는 동안은 CAR expression.</li>
<li>Tumor antigen을 CAR T Cell이 보게 되면서 죽이게 된다.</li>
<li>Target selection

<ul>
<li>가장 중요한 것.</li>
<li>Protein 등 - tumor specific target인 것이 중요하다.</li>
<li>어떻게 하면 on-target, off-target toxicity를 줄일 수 있을까? off-target, off-target toxicity 줄여야함.</li>
</ul></li>
<li>CD19 and other B cell markers (Stem cells - mature B)</li>
<li>Normal B cell -&gt; not tumor specific함.</li>
<li>Signal 1만 막아. Signal2 - CD28, 4-1BB, OX-40 | signal 2가 없으면 anergic - First gen CAR에서는 실패. 2nd gen CAR는 CD28, 4-1BB, OX40</li>
<li>3rd gen CAR에서는 임상에서 많이 사용되지는 않는다.</li>
</ul>

<p><img src="http://d3md5dngttnvbj.cloudfront.net/content/bloodjournal/125/26/4017/F1.large.jpg" alt="CAR generation" /></p>

<ul>
<li>Cell production - T cell expansion by dynabeads - 19-28z+ vector와 T cell을 섞어줌. 19-28z+ transduced T cells | CTCEF</li>
<li>GVHD minimal risk</li>
<li>ALL - CLL과 다르게 proliferation 빠르다.</li>
<li>Relapsed ALL은 Px - poor</li>
<li>Post-CAR T cell infusion</li>
<li>No cure. 5년정도 F/U</li>
<li>Clinical Trial</li>
<li><sup>4</sup>&frasl;<sub>18</sub> relapse</li>
<li>Overall survival - relapse하긴 하나</li>
<li>Murine - T cell - Flow cytometry통해서.</li>
<li>cytokine release syndrome</li>
<li>Tc 얼마나 last하는가는 key question</li>
<li>어느정도 lasting하는가? - NEJM 2014 - Maude

<ul>
<li>소아라서 Quality가 다를 수 있는 확률이 있어.</li>
</ul></li>
<li>CRS - fever, hypotension, resp insufficiency - 7일정도</li>
<li>Neurological changes - delirium, global encephalopathy, aphasia, seizure-like activities/seizure</li>
<li>disease burden 많으면 severe CRS - correlation이 있다.</li>
<li>CRP - IL-6 release 높아져.

<ul>
<li><a href="https://en.wikipedia.org/wiki/Tocilizumab">Tocilizumab</a></li>
<li>humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.</li>
<li>Steroid</li>
</ul></li>
</ul>

<h3 id="summary">Summary</h3>

<ul>
<li>High CR rates can be achieved in both adults and children with R/R B-ALL</li>
<li>Durable response - no subsequent allo-SCT</li>
<li>CRS - mc AE a/w CD19 CAR T cells - toci, steroid</li>
<li>Neurotoxicity - difficult</li>
</ul>

<h3 id="additional-comments">Additional comments</h3>

<ul>
<li>The hostile Tumor microinvironment</li>
<li>Armored CARs

<ul>
<li>genetic modification - IL12, CD40L</li>
<li>PD-1 K/O할수도 있고..</li>
</ul></li>
<li>IL-12

<ul>
<li>IL-12 pro-inflammatory - IV infusion힘들어.</li>
<li>IL-12 secretion-&gt; NK cells &amp; Anergic TIL -&gt;</li>
</ul></li>
<li>CD40L

<ul>
<li>Armored CD40L CAR</li>
</ul></li>
</ul>

<h3 id="for-the-future">For the future</h3>

<ul>
<li>Less cumbersome, 3rd party, 더 강한 Tc, solid tumor에서 적용,</li>
</ul>

<h3 id="conclusions">Conclusions</h3>

<ul>
<li>Autologous CD19-Targeted</li>
<li>High response rate이지만 perfect하지 않음</li>
<li>왜 resistance일어나는지?</li>
<li>CLL, ALL 다른점 무엇인지?</li>
<li>heme malignancies-&gt; applicability 있는지? solid tumor로 갈수 있을지?</li>
<li>target selection</li>
</ul>

<h3 id="my-question">My Question</h3>

<p>Dynabeads를 통해 polyclonal activation된 후 filter할 수 없나?</p>

<h3 id="questions">Questions</h3>

<ul>
<li>Car T cell in CSF - Yes</li>
<li>41BB PD-1</li>
</ul>

<p><img src="http://www.danafarberbostonchildrens.org/uploadedimages/content/page_content/news/2015/dfc_7706_car_t-cell_infographic_branded-2.jpg" alt="enter image description here" /></p>

<h3 id="reference">Reference</h3>

<ul>
<li>Park J. et al. ASH 2015, Abstract 682</li>
<li>Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL. Jae Hong Park MD
<a href="http://meetinglibrary.asco.org/content/110503?media=vm">http://meetinglibrary.asco.org/content/110503?media=vm</a></li>
</ul>

    </div>
  </article>

  


</main>

      <footer class="footer">
        <ul class="footer-links">
          <li>
            <a href="../../../../index.xml" type="application/rss+xml" target="_blank">RSS feed</a>
          </li>
          <li>
            <a href="https://gohugo.io/" class="footer-links-kudos">Made with <img src="../../../../images/hugo-logo.png" width="22" height="22"></a>
          </li>
        </ul>
      </footer>

    </div>
    

    

    
  </body>
</html>

